Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France: Support for primary HDV screening in France.

Fiche publication

Date publication

février 2024

Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HABERSETZER François

Tous les auteurs :
Parfut A, Tripon S, Gantner P, Chaffraix F, Laugel E, Wendling MJ, Erol F, Wiedemer C, Doffoel M, Saviano A, Royant M, Habersetzer F, Fafi-Kremer S, Velay A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38350177

Résumé

Hepatitis Delta virus (HDV) infection is a major cause of liver-related morbidity and mortality in patients infected with HBV, with a global HDV prevalence uncertain. In France, 2 to 5 % of HBs antigen (HBsAg) carriers present anti-HDV antibodies (anti-HDV). The EASL recommends testing for anti-HDV in all HBsAg-positive patients. Since January 2022, we have systematically carried out anti-HDV serology when a positive HBsAg is discovered (new HBsAg carriers).